Literature DB >> 1824792

Glucose-induced exertional fatigue in muscle phosphofructokinase deficiency.

R G Haller1, S F Lewis.   

Abstract

BACKGROUND: The exercise capacity of patients with muscle phosphofructokinase deficiency is low and fluctuates from day to day. The basis of this variable exercise tolerance is unknown, but our patients with this disorder report that fatigue of active muscles is more rapid after a high-carbohydrate meal. METHODS AND
RESULTS: To determine the effect of carbohydrate on exercise performance, we asked four patients with muscle phosphofructokinase deficiency to perform cycle exercise under conditions of differing availability of substrate--i.e., after an overnight fast, and during an infusion of glucose or triglyceride (with 10 U of heparin per kilogram of body weight) after an overnight fast. As compared with fasting and the infusion of triglyceride with heparin, the glucose infusion lowered plasma levels of free fatty acids and ketones, reduced maximal work capacity by 60 to 70 percent, and lowered maximal oxygen consumption by 30 to 40 percent. Glucose also increased the relative intensity of submaximal exercise, as indicated by a higher heart rate at a given workload during exercise. The maximal cardiac output (i.e., oxygen delivery) was not affected by varying substrate availability, but the maximal systemic arteriovenous oxygen difference was significantly lower during glucose infusion (mean +/- SE, 5.5 +/- 0.3 ml per deciliter) than after fasting (7.6 +/- 0.4 ml per deciliter, P less than 0.05) or during the infusion of triglyceride with heparin (8.9 +/- 1.3 ml per deciliter, P less than 0.05).
CONCLUSIONS: In muscle phosphofructokinase deficiency, the oxidative capacity of muscle and the capacity for aerobic exercise vary according to the availability of blood-borne fuels. We believe that glucose infusion lowers exercise tolerance by inhibiting lipolysis and thus depriving muscle of oxidative substrate (plasma free fatty acids and ketones); this impairs the capacity of working muscle to extract oxygen and lowers maximal oxygen consumption.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1824792     DOI: 10.1056/NEJM199102073240603

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  12 in total

Review 1.  Myopathies Related to Glycogen Metabolism Disorders.

Authors:  Mark A Tarnopolsky
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

Review 2.  Metabolic Myoglobinuria.

Authors:  Emanuele Barca; Valentina Emmanuele; Salvatore Billi DiMauro
Journal:  Curr Neurol Neurosci Rep       Date:  2015-10       Impact factor: 5.081

Review 3.  Muscle glycogenoses: an overview.

Authors:  S Di Mauro
Journal:  Acta Myol       Date:  2007-07

4.  Deficiency of phosphofructo-1-kinase/muscle subtype in humans impairs insulin secretion and causes insulin resistance.

Authors:  M Ristow; M Vorgerd; M Möhlig; H Schatz; A Pfeiffer
Journal:  J Clin Invest       Date:  1997-12-01       Impact factor: 14.808

Review 5.  Treatment Opportunities in Patients With Metabolic Myopathies.

Authors:  Mette Cathrine Ørngreen; John Vissing
Journal:  Curr Treat Options Neurol       Date:  2017-09-21       Impact factor: 3.598

Review 6.  [Rhabdomyolysis and myoglobinuria].

Authors:  A Lindner; S Zierz
Journal:  Nervenarzt       Date:  2003-05-14       Impact factor: 1.214

7.  Diagnostic evaluation of rhabdomyolysis.

Authors:  Jessica R Nance; Andrew L Mammen
Journal:  Muscle Nerve       Date:  2015-03-14       Impact factor: 3.217

Review 8.  Exercise in muscle glycogen storage diseases.

Authors:  Nicolai Preisler; Ronald G Haller; John Vissing
Journal:  J Inherit Metab Dis       Date:  2014-10-18       Impact factor: 4.982

9.  Common mutations in the phosphofructokinase-M gene in Ashkenazi Jewish patients with glycogenesis VII--and their population frequency.

Authors:  J B Sherman; N Raben; C Nicastri; Z Argov; H Nakajima; E M Adams; C M Eng; T M Cowan; P H Plotz
Journal:  Am J Hum Genet       Date:  1994-08       Impact factor: 11.025

10.  Phosphofructo-1-kinase deficiency leads to a severe cardiac and hematological disorder in addition to skeletal muscle glycogenosis.

Authors:  Miguel García; Anna Pujol; Albert Ruzo; Efrén Riu; Jesús Ruberte; Anna Arbós; Anna Serafín; Beatriz Albella; Juan Emilio Felíu; Fátima Bosch
Journal:  PLoS Genet       Date:  2009-08-21       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.